Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005949/en/



Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

BusinessWire_EN 
0 21.04.20
Update on 92nd Vifor Pharma Ltd. Annual General Meeting
Update on 92nd Vifor Pharma Ltd. Annual General Meeting


Regulatory News:



Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2

BusinessWire_EN 
0 31.03.20
Update zur 92. Generalversammlung der Vifor Pharma AG
Update zur 92. Generalversammlung der Vifor Pharma AG


Regulatory News:



Vifor Pharma hat bestätigt, dass die Generalversammlung des Unternehmens wie geplant am 14. Mai 2020 abgehalten wird. Aufgrund der aktuellen Situation und im Einklang mit Art. 6a

BusinessWire_DE 
0 31.03.20
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance


Regulatory News:



Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The

BusinessWire_EN 
0 12.03.20
Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose
Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose


Regulatory News:



Die Vifor Pharma Gruppe erzielte 2019 ein starkes finanzielles und operatives Ergebnis dank Fokus auf die drei strategischen Wachstumstreiber und gezielten Investitionen in die

BusinessWire_DE 
0 12.03.20
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings


Regulatory News:



Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This investment

BusinessWire_EN 
0 03.03.20
Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio
Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio


Vifor Pharma today announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the second largest

BusinessWire_EN 
0 20.02.20
BB Biotech: Ausschau nach „lukrativen Anlagechancen“
BB Biotech: Ausschau nach „lukrativen Anlagechancen“

BB Biotech (WKN: A0NFN3) publiziert heute seine ersten Zahlen für das abgelaufene Geschäftsjahr. Aktionäre können sich freuen, denn als Dividende will die Schweizer Gesellschaft 3,40 CHF pro Aktie

sharedeals 
0 17.01.20
Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously
Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005728/en/



Iron Deficiency Day is an international event which

BusinessWire_EN 
0 26.11.19
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005734/en/



Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

BusinessWire_EN 
0 26.11.19
Vifor Pharma Appoints Lee Heeson as President International and Member of the Executive Committee
Vifor Pharma Appoints Lee Heeson as President International and Member of the Executive Committee


Regulatory News:



Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020.



Lee Heeson joins Vifor

BusinessWire_EN 
0 18.11.19
Vifor Pharma and Evotec form joint venture for early development in nephrology
Vifor Pharma and Evotec form joint venture for early development in nephrology


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005841/en/



Vifor Pharma and Evotec SE today announced the

BusinessWire_EN 
0 08.11.19
Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen
Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen


Regulatory News:



Vifor Pharma today announced a commercial partnership with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to jointly

BusinessWire_EN 
0 08.11.19
BB Biotech: Kurzfristige, temporäre Schwäche kaufenswert
BB Biotech: Kurzfristige, temporäre Schwäche kaufenswert

Der Schweizer Biotechnologie-Investor BB Biotech (WKN: A0NFN3) hat heute seine aktuellen Quartalszahlen vorgelegt. Demnach wurde in den ersten neun Monaten des laufenden Geschäftsjahres 2019 ein

sharedeals 
1 18.10.19
Santhera: Vamorolone droht zu scheitern – an der Konkurrenz!
Santhera: Vamorolone droht zu scheitern – an der Konkurrenz!

Große Hoffnung setzen Anleger von Santhera (WKN: A0LCUK) in den einlizenzierten DMD-Medikamentenkandidaten Vamorolone und übersehen dabei offensichtlich völlig: Das Steroid wird in Zukunft

sharedeals 
0 01.10.19
Can Marijuana Cure Alzheimer's Disease?
Can Marijuana Cure Alzheimer's Disease?
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of Aβ amyloid plaques and twisted tangles of a protein called "tau" in regions of the brain responsible for....
TheMotleyFool 
0 13.11.17
Why Advanced Accelerator Applications SA Acquired a Higher Price Today
Why Advanced Accelerator Applications SA Acquired a Higher Price Today
Advanced Accelerator Applications (NASDAQ: AAAP) is up 10.5% at 11:42 a.m. EDT after announcing that it was being acquired by Novartis (NYSE: NVS) for approximately $3.9 billion.Advanced....
TheMotleyFool 
0 30.10.17
3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
It's been a banner year for anyone who started 2017 holding shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), XOMA Corporation (NASDAQ: XOMA), or Dynavax Technologies Corporation (NASDAQ:....
TheMotleyFool 
0 29.10.17
5 Intriguing Things Illumina's Management Said in Its Q3 Update
5 Intriguing Things Illumina's Management Said in Its Q3 Update
"Let the good times roll" might be a good theme for Illumina (NASDAQ: ILMN) in 2017. The gene-sequencing pioneer reported its third-quarter results on Tuesday. Illumina once again beat....
TheMotleyFool 
0 26.10.17
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Gilead Sciences (NASDAQ: GILD) recently acquired clinical-stage CAR-T drugmaker Kite Pharma, for $11.9 billion and on Wednesday, the FDA helped validate the company's purchase price by approving....
TheMotleyFool 
0 20.10.17
Amgen Wins Reprieve on Its 2nd-Best-Selling Drug
Amgen Wins Reprieve on Its 2nd-Best-Selling Drug
The "composition of matter" patent protecting Amgen Inc.'s (NASDAQ: AMGN) white-blood-cell-boosting drug Neulasta from competition has already expired. That may mean it's only a matter of time....
TheMotleyFool 
0 11.10.17
Why Glaukos Corp. Stock Sank 12.8% in September
Why Glaukos Corp. Stock Sank 12.8% in September
After management decided to dial back revenue expectations for 2017, shares of Glaukos (NYSE: GKOS), a medical device maker focused on diseases of the eye, tumbled 13% in September, according to....
TheMotleyFool 
0 05.10.17
Why Advanced Accelerator Application SA Stock Jumped Higher Today
Why Advanced Accelerator Application SA Stock Jumped Higher Today
Shares of Advanced Accelerator Application (NASDAQ: AAAP) are up 12% as of 11:23 a.m. EDT after Bloomberg reported that Novartis (NYSE: NVS) is considering acquiring the radiopharmaceutical....
TheMotleyFool 
0 28.09.17
Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors
Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock has already tripled this year, on renewed hopes of success for an experimental lupus treatment. Despite this year's big run-up, this....
TheMotleyFool 
0 27.09.17
Why Are Cancer Drugs So Expensive?
Why Are Cancer Drugs So Expensive?
All drugs are costly to produce, but cancer drugs are notoriously expensive to push through to market, and every year, treatments get more and more expensive. In this clip from Industry Focus:....
TheMotleyFool 
0 20.09.17